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Abstract
Background: Characterization of lipoprotein particle 
profiles (LPPs) (including main classes and subclasses) 
by means of ultracentrifugation (UC) is highly requested 
given its clinical potential. However, rapid methods are 
required to replace the very labor-intensive UC method 
and one solution is to calibrate rapid nuclear magnetic 
resonance (NMR)-based prediction models, but the 
 reliability of the UC-response method required for the 
NMR calibration has been largely overlooked.
Methods: This study provides a comprehensive repeat-
ability and reproducibility study of various UC-based lipid 
measurements (cholesterol, triglycerides [TGs], free cho-
lesterol, phospholipids, apolipoprotein [apo]A1 and apoB) 
in different main classes and subclasses of 25 duplicated 
fresh plasma samples and of 42 quality control (QC) frozen 
pooled plasma samples of healthy individuals.
Results: Cholesterol, apoA1 and apoB measurements 
were very repeatable in all classes (intraclass correla-
tion  coefficient [ICC]: 92.93%–99.54%). Free choles-
terol and phospholipid concentrations in main classes 
and subclasses and TG concentrations in high-density 
 lipoproteins (HDL), HDL subclasses and low-density lipo-
proteins (LDL) subclasses, showed worse repeatability 
(ICC: 19.21%–99.08%) attributable to low concentrations, 
variability introduced during UC and assay limitations. 
On frozen QC samples, the reproducibility of cholesterol, 
apoA1 and apoB concentrations was found to be better 
than for the free cholesterol, phospholipids and TGs 
concentrations.
Conclusions: This study shows that for LPPs measure-
ments near or below the limit of detection (LOD) in some of 
the subclasses, as well as the use of frozen samples, results 
in worsened repeatability and reproducibility. Further-
more, we show that the analytical assay coupled to UC for 
free cholesterol and phospholipids have different repeat-
ability and reproducibility. All of this needs to be taken 
into account when calibrating future NMR-based models.
Keywords: analytical variation; cholesterol; dyslipidemia; 
lipoproteins; quality control; triglycerides; variability.
Introduction
Lipoprotein particle profiles (LPPs) have been repeatedly 
shown to be a risk factor for cardiovascular disease (CVD) 
[1, 2]. LPs play an important role in lipid metabolism as 
transport vehicles of lipids (cholesterol and triglycerides 
[TGs]) in circulation. Commonly, LPs are classified based 
on density as very low-density lipoproteins (VLDL), low-
density lipoproteins (LDL), intermediate-density lipopro-
teins (IDL) and high-density lipoproteins (HDL). These 
four classes of LP, which can be further separated into 
subclasses, differ not only in size and density, but also 
in the composition of the lipids carried inside the parti-
cle and the type of apolipoproteins present in the particle 
membrane. LP class determines the source and function 
of the lipids transported inside. Therefore,  determination 
of LP composition can serve as a snapshot of the lipid 
 metabolism, making it possible to assess how lipid 
 metabolism differs in health and disease states [1–3].
The classical lipid panel, which typically provides 
measurements for total, LDL and HDL-cholesterol and 
for TGs, is widely used in clinical practice as it is simple, 
cheap and fast to measure. In general, the classical lipid 
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panel provides useful measurements and their  biological 
variability has been extensively studied in serum and 
plasma [4–6]. In some cases, LDL-cholesterol values are 
not measured directly, but simply estimated from total 
cholesterol, HDL-cholesterol and total TGs using, for 
example, the Friedewald or Martin equations [7–11]. The 
main drawback of the classical lipid panel is that it pro-
vides limited lipid information, as it only focuses on the 
cholesterol content of two of the main LP classes. More 
detailed profiling of the LPPs might improve our under-
standing of their role in health and disease as well as 
their diagnostic ability for CVD [1]. Thus, clinicians have 
stressed the importance of LPPs for CVD risk assessment, 
which makes routine characterization of LPPs using sep-
aration-based technologies and clinical assays for the 
determination of the concentrations of components of 
these LPs highly desirable. The limitations of the time-
consuming separation-based techniques have resulted in 
a quest for building NMR-based LPP prediction models. 
Nevertheless, a reference method is still necessary for 
the calibration of the rapid prediction method as well 
as for future maintenance of the calibration model. 
High-performance liquid chromatography (HPLC) and 
ultracentrifugation (UC) are two of the techniques used 
to separate the different LP fractions, containing the LP 
main classes and subclasses [12, 13]. UC exploits the dif-
ferences in density of the different lipoprotein classes for 
separation and remains the classical and most commonly 
used method for separating lipoprotein subclasses [14]. 
While UC provides much more information than the clas-
sical lipid panel, it is also cumbersome, time-consuming 
and very much dependent on the skills and experience 
of the operator. In the last two decades, effort has been 
put into developing rapid prediction models based on 
1H nuclear magnetic resonance (NMR) spectroscopy to 
determine LPPs in blood samples [15–21]. NMR spectra 
contain sufficient physicochemical information (i.e. the 
intensity and position of the complex methyl and methyl-
ene signals from lipids) to extract LPPs from the spectra 
by calibration to an external reference method [14]. When 
such a calibration method is established, the LPPs of 
future samples can be predicted from a carefully recorded 
NMR spectrum by the application of an appropriate cali-
bration model.
Regardless of whether UC combined with lipid anal-
ysis is used directly as a lipid profiling technique or as 
reference for NMR-based models, accurate and reliable 
LPPs are necessary to provide a correct picture of the lipid 
metabolism. Although UC is still widely used by research 
laboratories as part of the determination of compound 
concentrations in the main LP classes and subclasses, 
very little attention has been given to the repeatability, 
reproducibility and recovery of the complete LPPs (includ-
ing subclasses). Pagani and  Panteghini have  contributed 
by studying within-subject and analytical variability in 
TGs, cholesterol, apolipoprotein (apo)A1 and B in serum, 
LDL, HDL, HDL2 and HDL3 (n = 10 healthy subjects) [22].
In the present work, we provide a thorough and 
 comprehensive repeatability, reproducibility and recov-
ery study of lipid measurements (cholesterol, TGs, phos-
pholipids, free cholesterol, apoB and apoA1) in plasma, 
main LP classes (VLDL, IDL, HDL and LDL) and LP sub-
classes (HDL2a, HDL2b, HDL3, LDL1, LDL2, LDL3, LDL4, 
LDL5 and LDL6) separated by UC. To the best of our knowl-
edge, this is the first paper to comprehensively describe 
figures of merit of measuring LPPs (including HDL and 




Male and female participants older than 20 years, with BMI  ranging 
from 18.5 to 40 kg/m2, who had not received antibiotic treatment 
3  months prior to the beginning of the study and who had not 
received pre- or probiotics 1  month prior to the beginning of the 
study, were included as part of the COUNTERSTRIKE (COUNTERact-
ing Sarcopenia with proTeins and exeRcise – Screening the CALM 
cohort for lIpoprotein biomarKErs) cohort. Pregnant and lactat-
ing women, as well as individuals suffering from CVD,  diabetes or 
chronic gastrointestinal disorders, were excluded from the study. 
COUNTERSTRIKE participants were recruited in the Copenha-
gen region via press and online announcements and gave written 
consent to participate in the study. The study was conducted at 
the Department of Nutrition, Exercise and Sports at the Univer-
sity of Copenhagen, Denmark and was approved by the Research 
 Ethics Committees of the Capital Region of Denmark in accordance 
with the Helsinki Declaration (H-15008313) and the Danish Data 
 Protection Agency (2013-54-0522).
Samples
In this study, LPPs of fresh fasting plasma samples from 223 
 individuals of the COUNTERSTRIKE cohort were determined. One 
individual was excluded from further analysis due to  non-compliance 
to fasting. LPPs from 25 of the included 222  individuals were 
 determined twice in the same UC run (UC within-run duplicates), 
adding up to a total of 247 measurements of the different lipid and 
protein compositions. Additionally, LPPs in 42  measurements of 
one pooled QC material (aliquots from one  frozen pooled plasma 
from healthy adults) were measured, in  different UC runs,  during 
the span of 10 months, from November 2015 until August 2016 (UC 
 between-run replicates).
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Determination of lipoprotein particle profiles
Ultracentrifugation (UC): Main lipoprotein fractions (VLDL, IDL, HDL, 
LDL) and lipoprotein subfractions (HDL2a, HDL2b, HDL3, LDL1, LDL2, 
LDL3, LDL4, LDL5, LDL6) were separated by means of UC using a modi-
fied version of the Baumstark method [13] as illustrated in Figure 1 (see 
Supplementary Table 4 for densities). Several stock solutions were used 
for the separation steps (Supplementary Table 1). A detailed description 
of the UC method can be found in the Supplementary Data.
Determination of concentrations in plasma, main classes and 
 subclasses: Colorimetric and turbidimetric assays were performed 
on an ABX Pentra 400 analyzer (ABX Pentra; Horiba ABX,  Montpellier, 
France) to determine the plasma, main class and  subclass concentra-
tions of total cholesterol, TGs, apoA1 and apoB (ABX Pentra; Horiba 
Medical, France). Accuracy and precision testing of the assays are 
available from https://toolkits.horiba-abx.com/documentation/
index.php. The total cholesterol assay has been certified by the 
 Cholesterol Reference Method Laboratory Network (CRMLN) (https://
www.cdc.gov/labstandards/pdf/crmln/MFR_TC_CRMLN-508.pdf).
Free cholesterol and phospholipids were also determined using 
colorimetric and turbidimetric assays (MTI Diagnostics, Germany 
http://www.mti-diagnostics.com/produkte-1/index.html and Wako 
Diagnostics, Wako Chemicals, USA, http://www.wakodiagnostics.
com/r_free_cholesterol.html and http://www.wakodiagnostics.
com/r_phospholipids.html) due to concerns with the reproducibility 
and repeatability of the other assays (Supplementary Table 2). Our 
assays showed good agreement with external control references (Sup-
plementary Table 2). Measured concentrations were corrected for dilu-
tion effects occurring during the separation of the different LP classes. 
The dialysis step performed to separate the different LDL  subclasses 
in the UC process causes a systematical bias (due to  residues left in the 
dialysis sac) that can be corrected for when  calculating LDL subclass 
concentrations. For a given sample i, a  correction factor (c) for LDL 
subclass concentrations was calculated as indicated in equation 1. We 
calculated this factor by using cholesterol concentrations to ensure 
that the sum of cholesterol concentrations in the LDL subclasses adds 
up to the cholesterol concentration in the LDL main class (i.e. recov-
ery of LDL cholesterol concentrations from LDL subclass cholesterol 
concentrations is 100%). This is done to account for potential losses 
as part of the dialysis step. This  multiplicative  factor c was then used 
to correct LDL subclass  concentrations for all compounds.
 
[LDLchol]
[LDL1chol]  [LDL2chol] [LDL3chol] [LDL4chol] [LDL5chol] [LDL6chol]
ici
i i i i i i
=
+ + + + +
(1)
It is important to note that the UC method followed in this study 
consists of many steps and is coupled to secondary analytical 
assays (Figure 1). This generates many possible sources of error that 
can contribute and accumulate to diminishing the quality of the 
data. It is therefore important to include replicates and QC samples 
to ensure that the acquired data is repeatable and  reproducible.
Data analysis
Recovery of plasma concentrations from main classes and 
 subclasses was calculated as the ratio of the sum of main classes 
(and subclasses) concentrations to the total plasma concentra-
tions for each of the compounds measured. Repeatability of LP 
concentration measurements was evaluated for the fresh plasma 
duplicates (within-run duplicates) in terms of average within-
individual coefficient of variation (WCV, expressed as percentage) 
across replicate measurements and standard deviation (SD) of 
these WCV values. The single score intraclass correlation coef-
ficient (ICC) defined by a one-way random effects model, with 
95% confidence intervals (CIs), was also calculated to quantify 
the degree of absolute agreement of measurements [23]. For each 
measurement and subclass, outliers, as determined by a Grubbs 
test on the average of the two repeated measurements, were 
excluded prior to calculating WCV and ICC. A Shapiro-Wilk test 
was performed on the average of the two repeated measurements 
to test for normality. Logarithmic transformation was applied 
when data were not normally distributed to calculate ICCs. WCV 
and ICC were calculated excluding measurements below the 
limit of detection (LOD). Reproducibility was assessed in frozen 
pooled QC samples (between-run replicates) in terms of CV, also 
 excluding measurements below the LOD.
Rationale of the approach
As there are no standards available for all LPP measurements as 
described, it is not possible to evaluate trueness and accuracy as fig-
ures of merit in the traditional way. The definition of recovery as 
we used it, is based on the facts that (i) theoretically the subclass 
concentrations should add up to the main class concentration and 
(ii) the concentration in the main class is higher and thus expected 
to be above LOD and reliable. It is not possible to evaluate the 
between-run reproducibility of the fresh samples, as the samples 
cannot be kept fresh for a long time. Hence, we chose to quantify 
reproducibility using the (frozen) QC samples. In a similar fashion, 
repeatability of the QC samples was not deemed representative for 
the repeatability of the measurements of the fresh samples. Ideally, 
an experimental design is used to study repeatability and reproduc-
ibility simultaneously using analysis of variance models to disen-
tangle the different contributions, but this is not possible given the 
mentioned limitations.
Results
Recovery of plasma concentrations from 
main classes and subclasses concentrations
Overall, the participants included in the analyses had 
plasma lipid levels within the normal/upper normal range 
(see Table 1 and Supplementary Table 3). The recovery 
of plasma concentrations from the sum of main class or 
 subclass concentrations (expressed as a  percentage) can 
serve as an indicator of the consistency of UC-derived 
LPP concentrations. Figure 2 shows the sum of the 
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concentrations in the main classes and in all subclasses 
vs. the plasma concentration for each of the compounds 
measured (recovery).
The values below the LOD were excluded from 
analysis by inserting a zero value. In Supplementary 
Figure 1, values below the LOD are substituted with the 
Figure 1: UC workflow followed to separate lipoprotein particle main fractions and subfractions, based on the Baumstark method [13].
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LOD value for comparison of how below-LOD measure-
ments affected the recovery. The included regression 
lines show that there are no systematic deviations in the 
recovery across the concentration range included in the 
cohort. Plasma cholesterol, TGs, apoB and apoA1 con-
centrations can be well recovered from both the main 
classes and the subclasses. Plasma free cholesterol and 
phospholipids concentrations, especially the former, 
are not as well recovered as the other compounds, 
neither from main classes nor from  subclasses concen-
trations. In the case of free cholesterol, the recovered 
concentrations from main fractions and subfractions 
are systematically higher than the original plasma con-
centrations. This, together with the fact that the recov-
eries for different measurements are scattered around 
the 100% recovery line, might be an initial indicator of 
the presence of high measurement errors for free cho-
lesterol (Figure 2). It is observed that the recovered con-
centrations for the rest of the compounds (cholesterol, 
TGs, phospholipids, apoA1 and apoB) are systemati-
cally lower than the plasma concentrations. This may 
be due to lost material during the UC process and/or 
during lipid and apolipoprotein analysis. An apparent 
inconsistency is found by the fact that, for most com-
pounds, the sum of concentrations of the main classes 
is smaller than the sum of concentrations of the sub-
classes. This inconsistency is probably related to the 
HDL class, as the LDL subclass concentrations are 
corrected for the dialysis effect. Munroe et al. showed 
that the high rotor speeds (>30,000 rpm) used during 
the separation of the HDL fraction results in shearing 
of the original LP and loss of protein, and which can 
in turn introduce variability during the separation of 
classes [24]. In order to test for potential overlap of 
certain particle types in the  different density fractions 
apoB in HDL and apoA1 in IDL and LDL was examined. 
However, we did not find significant amounts (apoB 
and apoA1 were well below the LOD) (data not shown) 
and thus this cannot explain the  systematically lower 
observations.
Repeatability of within-run duplicate 
samples (fresh plasma)
In order to investigate the repeatability of UC measure-
ments, the 25  within-run duplicates of the COUNTER-
STRIKE cohort were analyzed. Most UC measurements 
appear to be repeatable except for free cholesterol (Table 
1, Figure 3). Overall, the repeatability of cholesterol, 
apoA1 and apoB measurements are high and all these 
measurements were above the LOD. TG measurements 
in some HDL subclasses (HDL2a, HDL3), the HDL main 
class and some LDL  subclasses (LDL3, LDL4, LDL5, LDL6) 
were more  problematic as they show low repeatability 
(low ICC with very broad 95% CI) and high within-run 
variability in terms of WCV (Table 1). It is important to 
note that many TGs measurements in the problematic 
class and  subclasses (HDL, HDL2a, HDL3, LDL3, LDL4 
and LDL6) are below or just slightly above the LOD of 
7  mg/dL. Among others, this decreases the number of 
replicate measurements available for the repeatability 
calculations.
For free cholesterol and phospholipids, two  different 
assays were used (MTI and Wako diagnostics). Better 
repeatability is observed for the Wako assays when high 
concentrations of phospholipids and free cholesterol are 
present, as is the case for plasma concentrations (WCV of 
5.93 ± 10.1 and ICC of 79.85% with MTI vs. WCV of 1.5 ± 0.72 
and ICC of 99.37% with Wako for plasma free cholesterol, 
and WCV of 1.56 ± 1.46 and ICC of 99.26% with MTI vs. 
WCV of 1.31 ± 0.41 and ICC of 96.77% with Wako for plasma 
phospholipids). From the results for free cholesterol of the 
main classes no clear preference for one of the two assays 
can be derived. Note also that in some cases the number 
of repeats is low, hampering a proper calculation of the 
figures of merit.
Reproducibility of QC samples (frozen pooled 
plasma)
To further investigate the long-term reproducibility of 
UC measurements and the factors that contribute to it, 
repeated between-run measurements of QC samples 
were analyzed. Table 2 illustrates the reproducibility in 
plasma, main class and subclass measurements (see also 
Figure 4). Between-run reproducibility in frozen pooled 
samples proved to be much lower than within-run 
repeatability in fresh plasma (Tables 1 and 2). As already 
observed in within-run duplicates, poor between-run 
reproducibility is observed for phospholipids and free 
cholesterol measurements when compared to choles-
terol, apoA1 and apoB measurements. The reproducibil-
ity of the UC measurements for the two free cholesterol 
and phospholipids assays used (MTI  Diagnostics and 
Wako Diagnostics) were analyzed  separately (Table 2). 
CV ranges from 4.94% (LDL-cholesterol) to 75.3% (IDL 
phospholipids measured with the MTI Diagnostics assay) 
(Table 2). Possible trends in concentrations present in 
the QC measurements over time were also investigated 
(Supplementary Figure 2). For most measurements, no 
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Table 1: Mean and SD of within-individual means across duplicates (mg/dL), average WCV ± SD, expressed as percentage, across duplicates 
and ICC (expressed as percentage) with 95% CI of the different measurements in plasma, main classes and subclasses of the duplicate 
plasma samples of the COUNTERSTRIKE cohort.
Compound   Class   Mean  SD  WCV ± SD, %  ICC (95% CI), %   # Duplicates
Cholesterol   Plasma   181.96  38.57  1.14 ± 1.14  99.39 (98.65, 99.73)   25
  VLDLa   9.35  5.02  4.9 ± 4.77  98.37 (96.38, 99.27)   25
  IDLa   6.27  4.09  4.22 ± 3.33  99.27 (98.38, 99.68)   25
  LDL   94.38  25.47  2.05 ± 1.57  98.98 (97.72, 99.55)   25
  LDL1   27.01  9.14  3.28 ± 3.07  98.36 (96.23, 99.3)   23
  LDL2   15.71  4.83  4.05 ± 4.07  96.56 (92.32, 98.49)   24
  LDL3   14.09  4.79  2.42 ± 1.78  99.13 (98.02, 99.62)   24
  LDL4   12.62  4.44  3.77 ± 2.33  98.52 (96.66, 99.35)   24
  LDL5   10.45  3.68  3.92 ± 2.98  97.73 (94.9, 99.01)   24
  LDL6a   10.59  3.13  3.49 ± 2.65  97.56 (94.3, 98.97)   22
  HDLa   58.95  18.29  4.15 ± 2.8  97.25 (93.93, 98.77)   25
  HDL2ba   22.79  11.95  4.47 ± 3.1  98.95 (97.52, 99.56)   22
  HDL2a   21.84  6.02  3.26 ± 2.21  98.46 (96.46, 99.34)   23
  HDL3   14.39  3.26  3 ± 2.09  97.24 (93.7, 98.81)   23
TGs   PLASMA   90.15  31.42  1.55 ± 1.44  99.67 (99.27, 99.85)   25
  VLDLa   52.69  25.39  3.15 ± 3.6  98.88 (97.51, 99.5)   25
  IDL   7.16  2.50  9.33 ± 7.5  90.51 (79.9, 95.68)   25
  LDL   15.77  3.77  7.49 ± 5.36  87.11 (72.82, 94.18)   24
  LDL1   5.33  1.93  7.01 ± 7.63  96.27 (91.7, 98.36)   24
  LDL2a   2.53  0.56  12.32 ± 8.28  58.83 (17.72, 82.7)   17
  LDL3a   2.23  0.39  12.07 ± 10.01  38.09 (−19.65, 76.88)   12
  LDL4   2.31  0.30  16.71 ± 12.65  −21.8 (−72.93, 47.34)   9
  LDL5   2.16  0.36  12.24 ± 8.38  36.8 (−35.32, 82.77)   8
  LDL6   2.68  0.80  14.4 ± 11.85  68.53 (20.6, 90.3)   11
  HDLa   13.2  5.34  8.22 ± 6.63  91.96 (75.57, 97.59)   12
  HDL2ba   5.4  3.10  8.08 ± 11.19  92.45 (78.86, 97.49)   14
  HDL2a   7.58  1.80  5.75 ± 1.51  94.78 (39.88, 99.86)   3
  HDL3   3.12  0.59  14.4 ± 9.85  36.77 (−30.95, 80.81)   9
Free 
cholesterolb
  Plasma   57.01  11.21  5.93 ± 10.1  79.85 (55.62, 91.67)   19
  VLDL   6.66  0.86  12.38 ± 10.15  13.78 (−59.01, 76.51)   7
  IDL   6.8  2.06  2.43 ± 1.03  99.29 (89.19, 99.98)   3
  LDL   38.43  8.86  8.37 ± 11.82  72.85 (42.87, 88.51)   19
  LDL1   10.48  2.92  11.88 ± 12.44  80.81 (56.54, 92.31)   18
  LDL2   7.38  1.65  15.31 ± 15.69  42.72 (−7.42, 76.05)   15
  LDL3   6.11  1.41  24.48 ± 19.78  −1.67 (−47.21, 45.18)   17
  LDL4   5.81  1.53  16.34 ± 18.86  39.5 (−13.28, 75.33)   14
  LDL5   5.34  1.24  16.9 ± 20.44  22.42 (−31.24, 65.89)   14
  LDL6   5  1.14  7.78 ± 15.92  44.25 (−12.43, 79.74)   12
  HDL   27.98  8.66  9.52 ± 9.73  78.81 (41.06, 93.74)   11
  HDL2b   12.83  6.29  15.39 ± 19.53  92.21 (76.28, 97.67)   12
  HDL2aa   13.6  3.16  5.49 ± 5.99  88.12 (65.33, 96.39)   12
  HDL3   6.31  0.67  3.8 ± 4.2  79.01 (30.64, 95.33)   8
Free 
cholesterolc
  Plasma   65.4  14.50  1.5 ± 0.72  99.37 (96.27, 99.91)   6
  VLDL   9.43  0.00  0.17 ± 0  NA   1
  IDL   5.68  0.61  6.83 ± 1.29  67.06 (−51.96, 99)   3
  LDL   42  7.34  1.86 ± 1.9  98.49 (91.31, 99.78)   6
  LDL1   12.38  6.09  11.74 ± 8.96  91.6 (58.41, 98.75)   6
  LDL2   7.05  1.62  10.26 ± 8.64  69.37 (−3.97, 94.95)   6
  LDL3   5.74  1.49  23.22 ± 12.85  42.53 (−41.42, 89.07)   6
  LDL4a   6.15  1.86  8.65 ± 10.57  84.91 (10.22, 98.92)   4
  LDL5   5.42  1.64  7.13 ± 8.59  91.73 (39.82, 99.43)   4
  LDL6   5.47  1.09  7.3 ± 5.49  82.33 (26.57, 97.26)   6
  HDL   21.39  4.78  3.39 ± 2.55  96.72 (78.04, 99.64)   5
  HDL2b   10.26  1.46  5.12 ± 1.52  86.84 (17.46, 99.07)   4
  HDL2a   9.44  1.44  1.57 ± 1.97  NA   2
  HDL3   5.23  0.57  4.82 ± 3.42  78.21 (5.08, 97.42)   5
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clear trends were observed, except for TGs measure-
ments in LDL3, LDL4, LDL5, LDL6, HDL2a, HDL2b and 
HDL3, which are below or slightly above the LOD of 
7  mg/dL. In the case of phospholipids and free choles-
terol approximately the second half of the samples is 
closer to the mean (less deviation), which is explained 
by the fact that for these samples the Wako assays (with 
better  reproducibility) were used. In conclusion, it 
becomes clear that the Wako Diagnostics phospholipid 
and free  cholesterol assays improved the measurement 
 repeatability and reproducibility, which confirms that 
the choice of assay is paramount.
Compound   Class   Mean  SD  WCV ± SD, %  ICC (95% CI), %   # Duplicates
Phospholipidsb   Plasma   209.02  45.25  1.56 ± 1.46  99.26 (98.12, 99.71)   19
  VLDLa   15.01  6.38  8.82 ± 8.11  91.77 (77.11, 97.25)   14
  IDL   13.75  0.00  1.85 ± 0  NA   1
  LDL   54.57  11.37  8.86 ± 11.08  74.41 (44.51, 89.52)   18
  LDL1   16.54  5.49  6.9 ± 5.32  93.23 (82.74, 97.47)   17
  LDL2   9.19  2.31  7.39 ± 7.5  84.53 (59.68, 94.7)   14
  LDL3   8.04  1.58  7.51 ± 5.99  77.76 (43.41, 92.56)   13
  LDL4   7.4  0.87  8.3 ± 6.64  38.36 (−22.2, 78.32)   11
  LDL5   7.5  2.34  7.11 ± 9.49  85.4 (47.44, 96.84)   8
  LDL6a   10.02  5.38  7.25 ± 7.05  94.97 (82.23, 98.71)   10
  HDLa   96.9  46.07  5.65 ± 4.92  97.09 (92.76, 98.86)   19
  HDL2ba   43.22  35.67  8.58 ± 9.16  97.67 (93.65, 99.17)   16
  HDL2aa   38.41  17.65  4.78 ± 4.42  97.55 (92.8, 99.2)   14
  HDL3   21.88  5.99  3.75 ± 2.91  96.94 (91.95, 98.87)   17
Phospholipidsc   Plasma   274.98  20.91  1.31 ± 0.41  96.77 (78.34, 99.65)   5
  VLDL   13.23  2.19  6.69 ± 7.01  76.65 (−13.75, 98.26)   4
  IDL   10.61  1.28  5 ± 2.19  81.21 (−24.91, 99.47)   3
  LDL   82.51  19.43  3 ± 2.23  97.38 (85.28, 99.62)   6
  LDL1   26.75  12.80  5.71 ± 4.67  98.55 (91.65, 99.79)   6
  LDL2   13.23  3.51  8.39 ± 5.8  91.69 (58.8, 98.77)   6
  LDL3   12.12  3.35  7.45 ± 6.71  89.39 (49.77, 98.41)   6
  LDL4   10.57  3.87  10.45 ± 7.9  90.99 (55.94, 98.66)   6
  LDL5   9.4  3.71  10.4 ± 7.03  88.55 (38.08, 98.71)   5
  LDL6   9.88  2.94  6.84 ± 4.98  93.12 (64.84, 98.98)   6
  HDL   111.53  32.27  4.16 ± 2.65  96.87 (82.6, 99.54)   6
  HDL2b   39.67  14.42  3 ± 1.86  99.08 (94.61, 99.87)   6
  HDL2a   46.59  11.86  3.97 ± 5.9  96.84 (82.47, 99.54)   6
  HDL3   30.21  6.67  4.41 ± 4.46  93.81 (67.88, 99.09)   6
ApoB   Plasma   86.81  19.92  1.2 ± 0.92  99.54 (98.97, 99.79)   25
  VLDL   4.64  1.81  3.91 ± 5.69  97.04 (93.49, 98.68)   25
  IDLa   3.99  2.03  3.42 ± 3.86  98.95 (97.67, 99.54)   25
  LDL   65.77  15.58  1.8 ± 1.54  99.08 (97.96, 99.59)   25
  LDL1   16.4  4.68  5.73 ± 4.18  92.93 (84.3, 96.92)   23
  LDL2   10.23  2.77  4.8 ± 4.24  94.83 (88.57, 97.72)   24
  LDL3   9.49  2.83  3.55 ± 2.53  97.63 (94.66, 98.96)   24
  LDL4   8.82  2.86  3.86 ± 3.47  97.61 (94.63, 98.95)   24
  LDL5   7.63  2.80  4.64 ± 3.16  96.76 (92.76, 98.58)   24
  LDL6   8.44  2.73  3.08 ± 3.04  98.18 (95.74, 99.24)   22
ApoA1   Plasmaa   144.82  32.50  1.19 ± 0.99  99.48 (98.84, 99.77)   25
  HDLa   123.87  31.63  3.83 ± 2.71  96.37 (91.9, 98.4)   24
  HDL2ba   34.19  19.67  3.91 ± 3.46  99.2 (98.02, 99.68)   20
  HDL2a   42.62  14.13  3.14 ± 3.26  98.49 (96.46, 99.37)   22
  HDL3   50.69  8.59  2.36 ± 2.06  96.68 (92.29, 98.6)   22
aFor the calculation of the ICC, measurements were log-transformed, ensuring normality. bFree cholesterol and phospholipids measurements 
obtained with MTI assays. cFree cholesterol and phospholipids measurements obtained with Wako assays. ApoA1, apolipoprotein A1; ApoB, 
apolipoprotein B; CI, confidence interval; ICC, intraclass correlation coefficient; HDL, high-density lipoproteins; IDL, intermediate-density 
lipoproteins; LDL, low-density lipoproteins; VLDL, very low-density lipoproteins; WCV, within-individual coefficient of variation (WCV).
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Discussion
This study provides, for the first time, figures of merit 
for a method using UC coupled with colorimetric and 
turbidimetric assays. The study shows that cholesterol, 
apoB and apoA1 concentrations can be measured in a 
repeatable and reproducible manner in plasma, main 
classes and subclasses. Thus, these results can reliably 
be used for calibration of rapid prediction models. The 
results further indicate that the presence of low con-
centrations contributes to a decreased repeatability in 
fresh plasma and to lower between-run reproducibility 
in pooled frozen plasma, respectively. This highlights 
that at low concentrations, a decreased reproducibility 
needs to be considered when calibrating new models for 
predicting the LOD. This could be accommodated for by 
down-weighting these observations in building a cali-
bration model. This is particularly problematic in frac-
tions where the concentration levels are close to the LOD 
of the UC-based measurements, which is the case for 
TGs concentrations in HDL and some LDL subclasses, as 
well as for free cholesterol and phospholipids concen-
trations in various classes. In future studies, including 
an analytical step for enrichment of these low concen-
tration analytes might be of interest to better be able to 
determine reproducibility and improve further calibra-
tion modeling.
Moreover, the choice of assay can have a big impact 
on the repeatability and reproducibility of concentra-
tions and our study provides a useful example for future 
experiments within LPP analysis. In this study, it was 
found that the phospholipids and free cholesterol meas-
urements acquired with the Wako Diagnostics assays are 
more repeatable and reproducible than those acquired 
with the MTI Diagnostics assay. It is paramount to choose 
assays that can handle relatively wide ranges of concen-
trations and that are able to measure low concentrations 
accurately. Despite the fact that the isolated subfraction 
Figure 2: Sum of concentrations (mg/dL) in main classes (black) and in subclasses (red) vs. total plasma concentrations of the different 
compounds measured in the samples of the COUNTERSTRIKE cohort.
Recovery (indicated in the legend) can only be calculated if there are no missing values in plasma, main class and subclass measurements. 
From the total of 247 samples, this condition was met in 224 samples for cholesterol, 210 for TGs, 223 for free cholesterol, 203 for 
phospholipids, 222 for apoB and 222 for apoA1. The black diagonal line represents a recovery of 100%. Legend reczero: recovery calculated 
substituting zero for the below LOD measurements; reg.coef: regression coefficients, intercept and slope; sub indicates subclasses.
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samples are very different from regular plasma samples 
and that the assays used for analysis were designed for 
regular plasma samples, no aberrant, abnormal or obvi-
ously erroneous assay behavior or results were observed 
and thus we assume that accurate and reliable measure-
ments were obtained. This is in line with the manufac-
turers testing of possible interfering agents, which also 
show no significant impact on the assay.
Our results show that repeatability in within-run 
duplicates (fresh plasma) is, as expected, better than the 
long-term reproducibility in the between-run QC samples 
(frozen pooled plasma) (Tables 1 and 2). Several factors 
might be contributing to this worse reproducibility in the 
case of the QC samples, one of them being the analysis of 
samples on different days. In future studies, including a 
repeatability test with frozen pooled plasma could be used 
in addition to the fresh plasma samples. However, another 
source of variability that is of special concern with the 
current method is the freeze-thaw cycle that the samples 
undergo prior to UC. This is in line with earlier findings 
of Castile and Taylor which already suggest that the 
freeze-thaw cycle results in an aggregation of liposomes 
[25]. In addition, the freeze-thaw cycle has been shown 
in the literature to introduce variability in the measure-
ments of cholesterol and TGs concentrations of serum 
main classes [26]. This study indicates that it is advisable 
to obtain UC LPPs on fresh blood samples when possible. 
Unfortunately, it is not possible to  determine long-term 
reproducibility in fresh plasma. As the QC measurements 
were taken during the span of 10 months, apart from the 
freeze-thaw cycle, storage time, change of calibration kits 
and slight room temperature variations might explain the 
apparent trends in the measurements and higher CVs. 
In spite of the lower reproducibility of measurements 
in frozen QC samples when compared to the repeatabil-
ity of duplicate fresh plasma samples, the variability in 
main classes measurements was found to be lower than 
in other studies that also used UC to separate LPs accord-
ing to density [4]. This study used a modified version of 
the Baumstark method, which utilized serum to perform 
the separation. As both serum and plasma samples are 
routinely used for lipoprotein measurements these results 
Figure 3: Average within-individual standard deviation vs. average within-individual mean (mg/dL) across the 25 COUNTERSTRIKE 
duplicates for each measured compound.
Here, concentrations refer to raw measurements (without correcting for dilution/dialysis effects). The red dotted line indicates the lower the 
LOD. Two different dilutions were made for apoB (in VLDL and IDL) thus two lower LOD lines are present.
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are most likely also be applicable for serum samples. 
However, further investigations are required to establish 
this with confidence [14].
The literature suggests that UC coupled with analytical 
assays is the preferred reference value for the calibration 
of NMR-based models for LPP determination [14]. Bathen 
et  al., Petersen et  al. and Ala-Korpela et  al. reported dif-
ficulties when modeling TG measurements in UC-derived 
HDL classes from plasma samples [17, 18, 27]. Bathen et al. 
already attributed this difficulty to the presence of low 
concentrations and to the small range of concentrations 
covered in the different samples, as well as to the low accu-
racy of the clinical assay used as a reference [18]. While 
acknowledging that the UC protocol, rotor and analyzer 
used in previous studies and the present one might differ, 
our results suggest that, apart from the presence of low 
concentrations and the variability introduced during the 
separation of these classes in UC [24], additional factors 
contributing to the difficulties in modeling the HDL main 
class and subclasses in some of the previous studies [17] 
might have been the variability introduced during the 
freeze-thaw cycling (Table 2). Other studies have shown 
that using UC as part of the beta quantification method for 
LDL- and HDL-cholesterol determination is highly accurate 
across laboratories and stable over time, however, similar 
comparisons for subclasses are lacking [28].
In conclusion, there are several factors that can 
affect repeatability and reliability of LPPs obtained 
by UC and these should be considered when building 
 calibration NMR-based models for LPP determination. It 
is paramount to acknowledge and understand unwanted 
variability in LPPs prior to building predictive models, 
as measurement errors introduced during separation by 
UC and during lipid or protein analysis can be propa-
gated into complex regression models. For this reason, 
it is advisable in future studies to include within-run 
duplicate and QC LPP measurements to the experi-
mental design for the acquisition of UC data from large 
cohorts that are going to be used to build calibration 
models. To exploit all benefits from fast, highly repeat-
able and reproducible secondary analytical prediction 
methods (e.g. NMR), it is important to strive to improve 
Figure 4: SD vs. average concentration (mg/dL) in the 42 QC samples for each measured compound.
Here, concentrations refer to raw measurements (without correcting for dilution/dialysis effects). Two different dilutions were made for 
apoB (in VLDL and IDL) thus two lower LOD lines are present.
Monsonis-Centelles et al.: Repeatability and reproducibility of lipoprotein particle subclasses      113
Table 2: Mean (mg/dL), SD and CV (expressed as percentage) of the different measurements in plasma, main classes and subclasses of the 
42 QC aliquots of the same frozen pooled plasma.
Compound Class Mean SD CV (%) # Samples
Cholesterol Plasma 169.55 14.21 8.38 42
VLDL 11.34 0.92 8.14 42
IDL 5.41 0.53 9.7 42
LDL 86.9 4.29 4.94 41
LDL1 26.12 3.6 13.79 39
LDL2 15.57 0.96 6.16 39
LDL3 14.08 1.16 8.23 39
LDL4 11.68 1.05 9.03 39
LDL5 9.31 0.89 9.61 39
LDL6 10.05 0.97 9.69 39
HDL 60.75 3.98 6.55 42
HDL2b 22.18 1.78 8.01 39
HDL2a 24.78 1.47 5.93 39
HDL3 15.78 2.95 18.68 39
TGs Plasma 101.86 8.13 7.99 42
VLDL 61.33 3.08 5.02 42
IDL 8.27 0.84 10.16 42
LDL 17.16 2.92 17.01 41
LDL1 5.75 0.96 16.71 39
LDL2 2.53 0.62 24.45 36
LDL3 2.4 0.44 18.53 29
LDL4 2.25 0.45 20.09 17
LDL5 2.11 0.37 17.43 16
LDL6 2.49 0.54 21.68 32
HDL 11.47 2.28 19.9 41
HDL2b 4.38 0.86 19.69 39
HDL2a 5.81 0.96 16.51 25
HDL3 3.21 0.82 25.42 29
Free cholesterol Plasma 55.44 (51.26) 4.39 (4.64) 7.92 (9.05) 25 (17)
VLDL 5.62 (5.7) 0.94 (1.88) 16.66 (32.98) 25 (17)
IDL 3.15 (2.52) 1.07 (0.65) 33.83 (25.93) 25 (16)
LDL 39.24 (31.44) 8.66 (3.66) 22.06 (11.64) 25 (16)
LDL1 11.02 (8.01) 2.51 (1.38) 22.79 (17.29) 24 (15)
LDL2 8.16 (5.93) 1.85 (1) 22.67 (16.79) 24 (15)
LDL3 4.8 (4.7) 2.02 (1.14) 42.07 (24.27) 24 (15)
LDL4 6.59 (4.83) 1.27 (1.17) 19.2 (24.13) 24 (15)
LDL5 4.96 (4.28) 1.72 (0.86) 34.67 (20.04) 24 (15)
LDL6 5.52 (4.15) 1.47 (0.96) 26.56 (23.06) 24 (15)
HDL 22.98 (18.09) 9.34 (4.71) 40.66 (26.06) 25 (17)
HDL2b 9.51 (7.66) 2.82 (1.26) 29.65 (16.42)  23 (16)
HDL2a 12.66 (8.49) 4.57 (1.95) 36.07 (23.02) 23 (16)
HDL3 5.87 (4.88) 2.48 (1.08) 42.24 (22.11) 23 (16)
Phospholipids Plasma 214.68 (231.08) 23.4 (21.43) 10.9 (9.27) 25 (17)
VLDL 14.39 (19.33) 4.67 (1.99) 32.48 (10.31) 25 (17)
IDL 5.17 (5.19) 3.66 (−) 70.86 (−) 6 (1)
LDL 51.47 (63.32) 13.6 (6.23) 26.42 (9.83) 25 (16)
LDL1 16.68 (18.05) 3.68 (2.42) 22.08 (13.41) 24 (15)
LDL2 9.29 (11.38) 2.40 (0.81) 25.85 (7.1) 22 (15)
LDL3 8.01 (10.37) 2.32 (0.74) 29.02 (7.09) 22 (15)
LDL4 7.03 (8.94) 1.56 (0.62) 22.2 (6.92) 18 (15)
LDL5 5.86 (6.98) 1.42 (0.87) 24.2 (12.43) 14 (15)
LDL6 6.67 (8.34) 1.53 (0.56) 22.96 (6.74) 17 (15)
HDL 102.58 (118.62) 18.6 (8.17) 18.13 (6.89) 25 (17)
HDL2b 34.62 (41.37) 5.87 (2.01) 16.94 (4.87) 23 (16)
HDL2a 44.63 (52.63) 8.45 (2.28) 18.94 (4.33) 23 (16)
HDL3 26.81 (34.06) 4.1 (8.55) 15.3 (25.1) 23 (16)
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the indispensable reference measurements of LPPs by 
standardizing protocols and choosing appropriate ana-
lytical assays that are able to measure reliably within the 
ranges of values covered in the population of interest.
Author contributions: All the authors have accepted 
responsibility for the entire content of this submitted 
manuscript and approved submission.
Research funding: This study was funded by the Danish 
Strategic Research Council/Innovation Foundation 
Denmark (COUNTERSTRIKE, grant number 4105-00015B).
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played 
no role in the study design; in the collection, analysis, and 
interpretation of data; in the writing of the report; or in the 
decision to submit the report for publication.
References
1. Superko HR. Advanced lipoprotein testing and subfractionation 
are clinically useful. Circulation 2009;119:2383–94.
2. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR.  
High density lipoprotein as a protective factor against coronary 
heart disease. The Framingham Study. Am J Med 1977;62:707–14.
3. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins – 
an integrated approach to mechanisms and disorders.  
N Engl J Med 1967;276:215–25.
4. Han S, Flattery AM, McLaren D, Raubertas R, Lee SH, Mendoza V,  
et al. Comparison of lipoprotein separation and lipid  analysis 
 methodologies for human and cynomolgus monkey plasma 
 samples. J Cardiovasc Transl Res 2012;5:75–83.
5. Smith SJ, Cooper GR, Myers GL, Sampson EJ. Biological variabil-
ity in concentrations of serum lipids: sources of variation among 
results from published studies and composite predicted values. 
Clin Chem 1993;39:1012–22.
6. Marcovina SM, Gaur VP, Albers JJ. Biological variability of 
 cholesterol, triglyceride, low- and high-density lipoprotein 
cholesterol, lipoprotein(a), and apolipoproteins A-I and B.  
Clin Chem 1994;40:574–8.
7. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the 
concentration of low-density lipoprotein cholesterol in plasma, 
without use of the preparative ultracentrifuge. Clin Chem 
1972;18:499–502.
8. Schectman G, Patsches M, Sasse EA. Variability in choles-
terol measurements: comparison of calculated and direct LDL 
 cholesterol determinations. Clin Chem 1996;42:732–7.
9. Fukuyama N, Homma K, Wakana N, Kudo K, Suyama A, Ohazama 
H, et al. Validation of the Friedewald equation for evaluation of 
plasma LDL-cholesterol. J Clin Biochem Nutr 2008;43:1–5.
10. Meeusen JW, Snozek CL, Baumann NA, Jaffe AS, Saenger AK. 
Reliability of calculated low-density lipoprotein cholesterol.  
Am J Cardiol 2015;116:538–40.
11. Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, 
Blumenthal RS, et al. Comparison of a novel method vs. the 
Friedewald equation for estimating low-density lipoprotein  
cholesterol levels from the standard lipid profile. J Am Med 
Assoc 2013;310:2061–8.
12. Okazaki M, Usui S, Ishigami M, Sakai N, Nakamura T, Matsu-
zawa Y, et al. Identification of unique lipoprotein subclasses for 
visceral obesity by component analysis of cholesterol profile in 
high-performance liquid chromatography. Arterioscler Thromb 
Vasc Biol 2005;25:578–84.
13. Baumstark MW, Kreutz W, Berg A, Frey I, Keul J. Structure of 
human low-density lipoprotein subfractions determined by X-ray 
Compound Class Mean SD CV (%) # Samples
ApoB Plasma 79.35 7.04 8.88 41
VLDL 5.97 0.5 8.39 41
IDL 3.96 0.34 8.5 41
LDL 61.53 3.44 5.59 40
LDL1 16.54 2.52 15.21 38
LDL2 10.31 0.8 7.79 38
LDL3 9.71 0.75 7.78 38
LDL4 8.26 0.69 8.35 38
LDL5 7.01 0.63 8.91 38
LDL6 8.17 0.75 9.15 38
ApoA1 Plasma 149.66 12.55 8.39 42
HDL 136.72 8.75 6.4 42
HDL2b 32.61 2.56 7.85 39
HDL2a 52.84 3.32 6.29 39
HDL3 57.06 11.16 19.55 39
Mean, SD and CV of the aliquots measurements acquired with the free cholesterol and phospholipids Wako assays are indicated in 
parenthesis. ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; CV, coefficient of variation; HDL, high-density lipoproteins;  
IDL, intermediate-density lipoproteins; LDL, low-density lipoproteins; SD, standard deviation; VLDL, very low-density lipoproteins.
Table 2 (continued)
Monsonis-Centelles et al.: Repeatability and reproducibility of lipoprotein particle subclasses      115
small-angle scattering. Biochim Biophys Acta – Protein Struct 
Mol Enzymol 1990;1037:48–57.
14. Aru V, Lam C, Khakimov B, Hoefsloot HC, Zwanenburg G, Lind 
MV, et al. Quantification of lipoprotein profiles by nuclear mag-
netic resonance spectroscopy and multivariate data analysis. 
TrAC – Trends Anal Chem 2017;94:210–9.
15. Mihaleva VV, Van Schalkwijk DB, De Graaf AA, Van Duynhoven 
J, Van Dorsten FA, Vervoort J, et al. A systematic approach to 
obtain validated partial least square models for predicting 
lipoprotein subclasses from serum nmr spectra. Anal Chem 
2014;86:543–50.
16. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analy-
sis by nuclear magnetic resonance spectroscopy. Clin Lab Med 
2006;26:847–70.
17. Petersen M, Dyrby M, Toubro S, Engelsen SB, Nørgaard L, 
Pedersen HT, et al. Quantification of lipoprotein subclasses by 
proton nuclear magnetic resonance-based partial least-squares 
regression models. Clin Chem 2005;51:1457–61.
18. Bathen TF, Krane J, Engan T, Bjerve KS, Axelson D. Quantifica-
tion of plasma lipids and apolipoproteins by use of proton NMR 
spectroscopy, multivariate and neural network analysis. NMR 
Biomed 2000;13:271–88.
19. Ala-Korpela M, Hiltunen Y, Bell JD. Quantification of biomedical 
NMR data using artificial neural network analysis: lipoprotein 
lipid profiles from 1H NMR data of human plasma. NMR Biomed 
1995;8:235–44.
20. Dona AC, Jimenez B, Schafer H, Humpfer E, Spraul M, Lewis 
MR, et al. Precision high-throughput proton NMR spectroscopy 
of human urine, serum, and plasma for large-scale metabolic 
phenotyping. Anal Chem 2014;86:9887–94.
21. Monsonis Centelles S, Hoefsloot HC, Khakimov B, Ebrahimi P, 
Lind MV, Kristensen M, et al. Toward reliable lipoprotein particle 
predictions from NMR spectra of human blood: an interlabora-
tory ring test. Anal Chem 2017;89:8004–12.
22. Pagani F, Panteghini M. Significance of various parameters 
derived from biological variability for lipid and lipoprotein analy-
ses. Clin Biochem 1993;26:415–20.
23. McGraw KO, Wong SP. Forming inferences about some intraclass 
correlation coefficients. Psychol Methods 1996;1:30–46.
24. Munroe WH, Phillips ML, Schumaker VN. Excessive cen-
trifugal fields damage high density lipoprotein. J Lipid Res 
2015;56:1172–81.
25. Castile JD, Taylor KM. Factors affecting the size distribution 
of liposomes produced by freeze-thaw extrusion. Int J Pharm 
1999;188:87–95.
26. Zivkovic AM, Wiest MM, Nguyen UT, Davis R, Watkins SM,  German 
JB. Effects of sample handling and storage on quantitative lipid 
analysis in human serum. Metabolomics 2009;5:507–16.
27. Ala-Korpela M, Korhonen A, Keisala J, Hörkkö S, Korpi P, Ingman 
LP, et al. 1H NMR-based absolute quantitation of human lipopro-
teins and their lipid contents directly from plasma. J Lipid Res 
1994;35:2292–304.
28. Nakamura M, Kayamori Y, Iso H, Kitamura A, Kiyama M, 
Koyama I, et al. LDL cholesterol performance of beta quan-
tification reference measurement procedure. Clin Chim Acta 
2014;20:288–93.
Supplementary Material: The online version of this article offers 
supplementary material (https://doi.org/10.1515/cclm-2019-0729).
